Chimeric Therapeutics Ltd (ASX:CHM) has received encouraging data from the second dose cohort of its CLTX CAR T Phase 1 dose escalation study for patients with recurrent or progressive glioblastoma.
The trial is underway at the City of Hope, one of the largest cancer research and treatment organisations in the United States, which developed and manufactured the therapy.
Dual-route adminstration
In this second dose cohort, CLTX CAR T cells were administered two ways – intratumorally and intraventricularly – at a total dose of 88 X 106 CLTX CAR T cells.
Clinicians observed positive initial safety and the dual routes of administration were well tolerated in the dose cohort. As the company has previously reported, all patients hit the 28-day follow-up milestone without experiencing dose-limiting toxicities.
Stability of disease
The good news went beyond dose tolerance – two-thirds of the evaluable patients treated achieved local stability of disease.
The company hopes to present additional insights into this cohort at a scientific congress as the trial progresses.
Third dose next
The study is now enrolling patients in the third dose cohort, which will administer CLTX CAR T cells to patients through the dual routes of administration at an increased total dose of 220 X 106 CLTX CAR T cells.
“This preliminary data is encouraging as it demonstrates safety with dual routes of administration," said Professor Behnam Badie MD, who oversees the brain tumour program at City of Hope.
"We now look forward to advancing the trial to higher dose levels which may provide more therapeutic benefit to patients.”